Physician profile
Jerilyn D Farmer
NPI 1366749152
$4,900.78
in general payments reported to CMS, 2019-2025
34 companies · $767 in 2025
The $767 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,152 · 2022: $1,292 · 2023: $780 · 2024: $910 · 2025: $767.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,456.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $857.38 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $723.08 | 2021-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $463.88 | 2021-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $281.05 | 2021-2024 | |
| Astrazeneca Pharmaceuticals Lp | $264.76 | 2021-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $242.26 | 2021-2025 | Camzyos, Eliquis |
| Baxter Healthcare | $237.70 | 2022 | |
| Pfizer INC. | $220.16 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.05 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $171.76 | 2022-2025 | General - Structural Heart, Watchman Access System |
| Esperion Therapeutics, INC. | $137.78 | 2021-2024 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $107.15 | 2022-2025 | Uptravi, Opsumit |
| Amgen INC. | $104.90 | 2021-2025 | Repatha, Repatha |
| Abbott Laboratories | $87.04 | 2021-2024 | Esprit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.25 | 2021-2025 | Lifevest |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $74.91 | 2022-2023 | Acticor 7 Vr-T Dx |
| Scpharmaceuticals INC. | $72.54 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $72.08 | 2021-2025 | |
| W. L. Gore & Associates, INC. | $59.85 | 2024 | Gore Viabahn Vbx Balloon Expandable Endo |
| Atricure, INC. | $51.63 | 2021 | |
| Daiichi Sankyo INC. | $50.22 | 2021-2024 | Injectafer |
| Kiniksa Pharmaceuticals International, Plc | $37.72 | 2024 | Arcalyst |
| Medtronic, INC. | $36.28 | 2022-2023 | Micra |
| Teva Pharmaceuticals USA, INC. | $29.12 | 2024 | Austedo Xr |
| Regeneron Healthcare Solutions, INC. | $27.81 | 2025 | Evkeeza |
| Veryan Medical Incorporated | $27.64 | 2022 | |
| Amarin Pharma, INC. | $27.44 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $27.42 | 2025 | Amvuttra |
| Azurity Pharmaceuticals, INC. | $27.08 | 2023-2024 | Edarbi, Edarbi |
| Kiniksa Pharmaceuticals, Ltd. | $21.11 | 2021 | |
| Medicure Pharma INC. | $19.27 | 2022 | |
| Chiesi USA, INC. | $15.48 | 2021 | |
| Novo Nordisk INC | $15.05 | 2024 | Wegovy |
| Arbor Pharmaceuticals, INC. | $12.93 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerilyn Farmer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.